COVID-19 Vaccine Licensing Public Health 
Bill of Health
JANUARY 12, 2023
Moderna also licensed their mRNA technology from Cellscript LLC – University of Pennsylvania’s successor-in-interest to the 966 patent. Indeed, as made public, the U.S. government committed more than one billion dollars to Moderna for development of its COVID-19 vaccines.
Bill of Health
SEPTEMBER 20, 2022
Fielding calls from heads of state, they decided what vaccine deliveries to prioritize , shaping which countries could protect lives and livelihoods. The answer to one of the most important public health questions of our time — who gets access to vaccines? — Private decisions did not match public health need.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bill of Health
AUGUST 29, 2022
Legally speaking, patent pledges are comparable to the open source software licenses that underlie much of the world’s technology infrastructure and the Creative Commons licenses that make billions of online images, videos and other content freely available (both discussed here ). Tesla and Toyota) to software (e.g,
Bill of Health
APRIL 7, 2022
The proposed compromise would allow for “the use of patented subject matter required for the production and supply of COVID-19 vaccines without the consent of the right holder to the extent necessary to address the COVID-19 pandemic, in accordance with the provisions of Article 31 of the Agreement, as clarified and waived.”
Bill of Health
APRIL 7, 2023
By Aparajita Lath Two articles published last month in the BMJ analyze the public investment and financing of mRNA COVID-19 vaccines, highlighting the extensive government funding that has supported the development of mRNA technology from 1985 to 2022. government substantially de-risking the vaccine development process.
Bill of Health
MARCH 24, 2022
Research funding contracts can help to safeguard against profound inequities in global allocation and distribution of lifesaving diagnostics, drugs, and vaccines. During large transnational public health crises, global demand soars for diagnostics, drugs, and vaccines. Using Contracts to Further Equity Goals.
Bill of Health
JANUARY 6, 2022
The National Institutes of Health (NIH) is currently embroiled in a dispute over the ownership of patent rights to Moderna’s flagship mRNA COVID-19 vaccine (mRNA-1273). Failing to do so would be a missed opportunity for the public sector to have a say in the distribution and pricing of this critical medical technology.
Expert insights. Personalized for you.
318 
Let's personalize your content